Strategic Acquisition: AbbVie's $1.4 billion acquisition of Aliada Therapeutics signals a significant bet on Alzheimer's disease treatment, bolstering its pipeline with a Phase I anti-amyloid...
Competitive Landscape: Roche CEO Thomas Schinecker urges regulators to block Novo Holdings' $16.5B acquisition of Catalent, citing concerns over reduced competition and potential negative impacts on...
Activist Investor Scrutiny: Starboard Value, a prominent activist investor, is calling for greater accountability from Pfizer's leadership over perceived overpaid M&A deals and poor returns on R&D...
Competitive Bidding Frenzy: Banks and private credit firms are engaged in an intense bidding war to secure a $5 billion debt financing deal for Bausch + Lomb, a prominent player in the eye care...
Strategic Rationale: The potential Cigna-Humana merger aims to achieve significant cost savings through economies of scale, enhancing their competitive position and offering more comprehensive...
Strategic Intervention: France acquires stake in Sanofi's Opella unit to safeguard jobs and national interests amid potential $16B sale to US firm CD&R. Pharmaceutical Landscape: Sanofi, a...
Corporate Governance Scrutiny: Pfizer's legal threats against former executives Ian Read and Frank D'Amelio for collaborating with activist investor Starboard Value have raised concerns about...
Strategic Shift: Sanofi's $16.4B deal to sell 50% stake in Opella consumer health unit to CD&R signals strategic focus on innovative medicines and vaccines. Industry Trend: Major pharma players like...
Strategic Pivot: Bausch + Lomb's exploration of a sale represents a strategic shift from its tumultuous spin-off process, aiming to streamline operations and unlock value. Market Positioning: With a...